Systemic, perioperative management of muscle-invasive bladder cancer and future horizons

Nature Reviews Clinical Oncology

Volumn 14, Issue 4, 2017, Pages 221-234

  Funt, Samuel A ^a   Rosenberg, Jonathan E ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATEZOLIZUMAB; AVELUMAB; DURVALUMAB; GEMCITABINE; NIVOLUMAB; PEMBROLIZUMAB; TICILIMUMAB; URELUMAB; ANTINEOPLASTIC AGENT; CISPLATIN; DEOXYCYTIDINE; TUMOR MARKER;

ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER STAGING; DNA REPAIR; DOSE DENSIFICATION; FEASIBILITY STUDY; GENE MUTATION; HUMAN; MUSCLE INVASIVE BLADDER CANCER; NONHUMAN; PERIOPERATIVE PERIOD; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREDICTOR VARIABLE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SURGICAL RISK; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME; ADJUVANT CHEMOTHERAPY; ANALOGS AND DERIVATIVES; CONSERVATIVE TREATMENT; CYSTECTOMY; EVIDENCE BASED MEDICINE; GENETICS; IMMUNOTHERAPY; LYMPH NODE METASTASIS; METABOLISM; MORTALITY; MUSCLE NEOPLASMS; MUTATION; PREOPERATIVE CARE; PROCEDURES; TIME FACTOR; TUMOR INVASION; URINARY BLADDER NEOPLASMS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; CHEMOTHERAPY, ADJUVANT; CISPLATIN; CYSTECTOMY; DEOXYCYTIDINE; DNA REPAIR; EVIDENCE-BASED MEDICINE; HUMANS; IMMUNOTHERAPY; LYMPHATIC METASTASIS; MUSCLE NEOPLASMS; MUTATION; NEOPLASM INVASIVENESS; NEOPLASM STAGING; ORGAN SPARING TREATMENTS; PREOPERATIVE CARE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS; URINARY BLADDER NEOPLASMS;

EID: 84996799514     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2016.188     Document Type: Review

References (155)

1. Jewett, H. J. & Strong, G. H. Infiltrating carcinoma of the bladder; relation of depth of penetration of the bladder wall to incidence of local extension and metastases. J. Urol. 55, 366-372 (1946).
2. Raghavan, D., Shipley, W. U., Garnick, M. B., Russell, P. J. & Richie, J. P. Biology and management of bladder cancer. N. Engl. J. Med. 322, 1129-1138 (1990).
3. Torre, L. A. et al. Global cancer statistics, 2012. CA Cancer J. Clin. 65, 87-108 (2015).
4. Edge, S., Byrd, D. & Compton, C. AJCC Cancer Staging Manual 7th edn (Springer, 2010).
5. American Cancer Society. Cancer Facts and Figures 2016. Cancer.org http://www.cancer.org/acs/groups/ content/@research/documents/document/acspc-047079.pdf (2016).
6. Wu, X.-R. Urothelial tumorigenesis: a tale of divergent pathways. Nat. Rev. Cancer 5, 713-725 (2005).
7. Pasin, E., Josephson, D. Y., Mitra, A. P., Cote, R. J. & Stein, J. P. Superficial bladder cancer: an update on etiology, molecular development, classification, and natural history. Rev. Urol. 10, 31-43 (2008).
8. Stein, J. P. et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J. Clin. Oncol. 19, 666-675 (2001).
9. Yafi, F. A. et al. Contemporary outcomes of 2287 patients with bladder cancer who were treated with radical cystectomy: a Canadian multicentre experience. BJU Int. 108, 539-545 (2011).
10. Vale, C. L. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data. Eur. Urol. 48, 202-206 (2005).
11. Montie, J. E. et al. Bladder cancer. J. Natl Compr. Canc. Netw. 7, 8-39 (2009).
12. Witjes, J. A. et al. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur. Urol. 65, 778-792 (2014).
13. Milowsky, M. I. et al. Guideline on muscle-invasive and metastatic bladder cancer (European Association of Urology Guideline): American Society of Clinical Oncology clinical practice guideline endorsement. J. Clin. Oncol. 34, 1945-1952 (2016).
14. Grossman, H. B. et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N. Engl. J. Med. 349, 859-866 (2003).
15. Galsky, M. D. et al. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol. 12, 211-214 (2011).
16. van der Hage, J. A. et al. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer Trial 10902. J. Clin. Oncol. 19, 4224-4237 (2001).
17. Rastogi, P. et al. Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27. J. Clin. Oncol. 26, 778-785 (2008).
18. Mauri, D., Pavlidis, N. & Ioannidis, J. P. A. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J. Natl Cancer Inst. 97, 188-194 (2005).
19. Pagano, F. et al. Results of contemporary radical cystectomy for invasive bladder cancer: a clinicopathological study with an emphasis on the inadequacy of the tumor, nodes and metastases classification. J. Urol. 145, 45-50 (1991).
20. Dalbagni, G. et al. Cystectomy for bladder cancer: a contemporary series. J. Urol. 165, 1111-1116 (2001).
21. Altekruse, S. et al. SEER Cancer Statistics Review, 1975-2007, National Cancer institute.Cancer.gov http://seer.cancer.gov/archive/csr/1975-2007/ (2011).
22. Donat, S. M. et al. Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience. Eur. Urol. 55, 177-186 (2009).
23. Paz-Ares, L. G. et al. Randomized phase III trial comparing adjuvant paclitaxel/gemcitabine/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: results of the Spanish Oncology Genitourinary Group (SOGUG) 99/01 study [abstract]. J. Clin. Oncol. 28, LBA4518 (2010).
24. Stadler, W. M. et al. Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. J. Clin. Oncol. 29, 3443-3449 (2011).
25. Cognetti, F. et al. Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial. Ann. Oncol. 23, 695-700 (2012).
26. Sternberg, C. N. et al. Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. Lancet Oncol. 16, 76-86 (2015).
27. Leow, J. J. et al. Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials. Eur. Urol. 66, 42-54 (2014).
28. Svatek, R. S. et al. The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder. Clin. Cancer Res. 16, 4461-4467 (2010).
29. Galsky, M. D. et al. Effectiveness of adjuvant chemotherapy for locally advanced bladder cancer. J. Clin. Oncol. 34, 825-832 (2016).
30. Yagoda, A., Watson, R. C., Gonzalez-Vitale, J. C., Grabstald, H. & Whitmore, W. F. Cis-dichlorodiammineplatinum(II) in advanced bladder cancer. Cancer Treat. Rep. 60, 917-923 (1976).
31. Yagoda, A. Phase II trials with cis-dichlorodiammineplatinum(II) in the treatment of urothelial cancer. Cancer Treat. Rep. 63, 1565-1572 (1979).
32. Herr, H. W. Cis-diamminedichloride platinum II in the treatment of advanced bladder cancer. J. Urol. 123, 853-855 (1980).
33. Soloway, M. S., Ikard, M. & Ford, K. Cis-diamminedichloroplatinum (II) in locally advanced and metastatic urothelial cancer. Cancer 47, 476-480 (1981).
34. Harker, W. G. et al. Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study. J. Clin. Oncol. 3, 1463-1470 (1985).
35. Sternberg, C. N. et al. Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J. Urol. 133, 403-407 (1985).
36. Logothetis, C. J. et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J. Clin. Oncol. 8, 1050-1055 (1990).
37. Loehrer, P. J. et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J. Clin. Oncol. 10, 1066-1073 (1992).
38. Saxman, S. B. et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J. Clin. Oncol. 15, 2564-2569 (1997).
39. Mead, G. M. et al. A randomized trial comparing methotrexate and vinblastine (MV) with cisplatin, methotrexate and vinblastine (CMV) in advanced transitional cell carcinoma: results and a report on prognostic factors in a Medical Research Council study. MRC Advanced Bladder Cancer Working Party. Br. J. Cancer 78, 1067-1075 (1998).
40. Scher, H. I. et al. Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) effect on the primary bladder lesion. J. Urol. 139, 470-474 (1988).
41. Millikan, R. et al. Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J. Clin. Oncol. 19, 4005-4013 (2001).
42. deVere White, R. W. et al. A sequential treatment approach to myoinvasive urothelial cancer: a phase II Southwest Oncology Group Trial (S0219). J. Urol. 181, 2476-2481 (2009).
43. Canter, D. et al. Clinicopathological outcomes after radical cystectomy for clinical T2 urothelial carcinoma: further evidence to support the use of neoadjuvant chemotherapy. BJU Int. 107, 58-62 (2011).
44. Meijer, R. P. et al. Response to induction chemotherapy and surgery in non-organ confined bladder cancer: a single institution experience. Eur. J. Surg. Oncol. 39, 365-371 (2013).
45. Culp, S. H. et al. Refining patient selection for neoadjuvant chemotherapy before radical cystectomy. J. Urol. 191, 40-47 (2014).
46. Apolo, A. B., Grossman, H. B., Bajorin, D., Steinberg, G. & Kamat, A. M. Practical use of perioperative chemotherapy for muscle-invasive bladder cancer: summary of session at the Society of Urologic Oncology annual meeting. Urol. Oncol. 30, 772-780 (2012).
47. Sternberg, C. N. et al. Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer 64, 2448-2458 (1989).
48. Dodd, P. M. et al. Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma. J. Clin. Oncol. 17, 2546-2546 (1999).
49. Herr, H. W., Donat, S. M. & Bajorin, D. F. Post-chemotherapy surgery in patients with unresectable or regionally metastatic bladder cancer. J. Urol. 165, 811-814 (2001).
50. Ho, P. L. et al. Outcome of patients with clinically node-positive bladder cancer undergoing consolidative surgery after preoperative chemotherapy: the M.D. Anderson Cancer Center Experience. Urol. Oncol. 34, 59.e1-59.e8 (2016).
51. Galsky, M. D. et al. Comparative effectiveness of treatment strategies for bladder cancer with clinical evidence of regional lymph node involvement. J. Clin. Oncol. 34, 2627-2635 (2016).
52. Apolo, A. B. et al. Clinical value of fluorine-18 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in bladder cancer. J. Clin. Oncol. 28, 3973-3978 (2010).
53. Splinter, T. A. et al. The prognostic value of the pathological response to combination chemotherapy before cystectomy in patients with invasive bladder cancer. European Organization for Research on Treatment of Cancer - Genitourinary Group. J. Urol. 147, 606-608 (1992).
54. Sonpavde, G. et al. Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy. Cancer 115, 4104-4109 (2009).
55. Tully, C. M., Bochner, B. H. & Dalbagni, G. Gemcitabine-cisplatin (GC) plus radical cystectomy-pelvic lymph node dissection (RC-PLND) for patients (pts) with muscle-invasive bladder cancer (MIBC): assessing impacts of neoadjuvant chemotherapy (NAC) and the PLND [abstract]. J. Clin. Oncol. 32 (Suppl. 4), 355 (2014).
56. Zargar, H. et al. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur. Urol. 67, 241-249 (2015).
57. Chism, D. D., Woods, M. E. & Milowsky, M. I. Neoadjuvant paradigm for accelerated drug development: an ideal model in bladder cancer. Oncologist 18, 933-940 (2013).
58. Funt, S. A. & Chapman, P. B. The role of neoadjuvant trials in drug development for solid tumors. Clin. Cancer Res. 22, 2323-2328 (2016).
59. Kassouf, W. et al. Outcome of patients with bladder cancer with pN+ disease after preoperative chemotherapy and radical cystectomy. Urology 73, 147-152 (2009).
60. Malmström, P. U. et al. Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. The Nordic Cooperative Bladder Cancer Study Group. J. Urol. 155, 1903-1906 (1996).
61. Sherif, A. et al. Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer - Nordic Cystectomy Trial 2. Scand. J. Urol. Nephrol. 36, 419-425 (2002).
62. International Collaboration of Trialists. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. Lancet 354, 533-540 (1999).
63. International Collaboration of Trialists. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 Trial. J. Clin. Oncol. 29, 2171-2177 (2011).
64. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352, 930-942 (1998).
65. Gill, S. et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J. Clin. Oncol. 22, 1797-1806 (2004).
66. David, K. A., Milowsky, M. I., Ritchey, J., Carroll, P. R. & Nanus, D. M. Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base. J. Urol. 178, 451-454 (2007).
67. Fedeli, U., Fedewa, S. A. & Ward, E. M. Treatment of muscle invasive bladder cancer: evidence from the National Cancer Database, 2003 to 2007. J. Urol. 185, 72-78 (2011).
68. Reardon, Z. D. et al. Trends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer: a sign of changing tides. Eur. Urol. 67, 165-170 (2015).
69. Lerner, S. P. et al. A phase III surgical trial to evaluate the benefit of a standard versus an extended pelvic lymphadenectomy performed at time of radical cystectomy for muscle invasive urothelial cancer: SWOG S1011 (NCT #01224665) [abstract MP65-02]. J. Urol. 193 (Suppl.), e807 (2015).
70. von der Maase, H. et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J. Clin. Oncol. 18, 3068-3077 (2000).
71. von der Maase, H. et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J. Clin. Oncol. 23, 4602-4608 (2005).
72. Dash, A. et al. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder. Cancer 113, 2471-2477 (2008).
73. National Comprehensive Cancer Network. Bladder Cancer (Version 1.2016). NCCN http://www.nccn.org/ professionals/physician-gls/pdf/bladder.pdf (2016).
74. Porter, M. P., Kerrigan, M. C., Donato, B. M. K. & Ramsey, S. D. Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancer. Urol. Oncol. 29, 252-258 (2011).
75. Sternberg, C. N. et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol No. 30924. J. Clin. Oncol. 19, 2638-2646 (2001).
76. Sternberg, C. N. et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur. J. Cancer 42, 50-54 (2006).
77. Choueiri, T. K. et al. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. J. Clin. Oncol. 32, 1889-1894 (2014).
78. Plimack, E. R. et al. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity. J. Clin. Oncol. 32, 1895-1901 (2014).
79. Blick, C. et al. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder. Cancer 118, 3920-3927 (2012).
80. Pouessel, D. et al. Pathologic down-staging following standard (SD) MVAC (methotrexate-vinblastine-doxorubicine-cisplatin) or dose-dense MVAC (DD) neoadjuvant chemotherapy (NC) for muscle-invasive urothelial bladder cancer (UC): a retrospective multicenter cohort of the French Genitourinary Tumor Group (GETUG/AFU) [abstract]. J. Clin. Oncol. 32, 4550 (2014).
81. Pouessel, D., Gauthier, H., Serrate, C., Pfister, C. & Culine, S. Dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy in bladder cancer: ready for prime time? J. Clin. Oncol. 32, 4168-4169 (2014).
82. Galsky, M. D. et al. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. Cancer 121, 2586-2593 (2015).
83. US National Library of Medicine. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02177695 (2016).
84. Bamias, A. et al. Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03). Ann. Oncol. 24, 1011-1017 (2013).
85. Plimack, E. et al. Neoadjuvant dose-dense gemcitabine and cisplatin (DDGC) in patients (pts) with muscle-invasive bladder cancer (MIBC): final results of a multicenter phase II study [abstract]. J. Clin. Oncol. 32 (Suppl. 5S), 4513 (2014).
86. Balar, A. et al. Multicenter prospective phase II trial of neoadjuvant (neo) dose dense gemcitabine and cisplatin (DD-GC) in patients (pts) with muscle-invasive bladder cancer (MIBC) [abstract]. J. Clin. Oncol. 34 (Suppl. 2S), 436 (2016).
87. Dash, A. et al. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer 107, 506-513 (2006).
88. Bellmunt, J. et al. Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer 80, 1966-1972 (1997).
89. Dogliotti, L. et al. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. Eur. Urol. 52, 134-141 (2007).
90. Petrioli, R. et al. Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients: a randomized phase II study. Cancer 77, 344-351 (1996).
91. Smith, D. C. et al. Phase II trial of paclitaxel, carboplatin and gemcitabine in patients with locally advanced carcinoma of the bladder. J. Urol. 180, 2384-2388 (2008).
92. Grivas, P. D. et al. A phase II trial of neoadjuvant nab-paclitaxel, carboplatin, and gemcitabine (ACaG) in patients with locally advanced carcinoma of the bladder. Urology 82, 111-117 (2013).
93. Hussain, S. A. et al. A study of split-dose cisplatin-based neo-adjuvant chemotherapy in muscle-invasive bladder cancer. Oncol. Lett. 3, 855-859 (2012).
94. Hutchins, L. F., Unger, J. M., Crowley, J. J., Coltman, C. A. & Albain, K. S. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N. Engl. J. Med. 341, 2061-2067 (1999).
95. Guancial, E. A. et al. Bladder cancer in the elderly patient: challenges and solutions. Clin. Interv. Aging 10, 939-949 (2015).
96. Hurria, A. et al. Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J. Clin. Oncol. 29, 3457-3465 (2011).
97. Montgomery, J. S., Miller, D. C. & Weizer, A. Z. Quality indicators in the management of bladder cancer. J. Natl Compr. Canc. Netw. 11, 492-500 (2013).
98. Perou, C. M. et al. Molecular portraits of human breast tumours. Nature 406, 747-752 (2000).
99. Prat, A., Ellis, M. J. & Perou, C. M. Practical implications of gene-expression-based assays for breast oncologists. Nat. Rev. Clin. Oncol. 9, 48-57 (2012).
100. von Minckwitz, G. et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J. Clin. Oncol. 30, 1796-1804 (2012).
101. Esserman, L. J. et al. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res. Treat. 132, 1049-1062 (2012).
102. Esserman, L. J. et al. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL - CALGB 150007/150012, ACRIN 6657. J. Clin. Oncol. 30, 3242-3249 (2012).
103. Sjödahl, G. et al. A molecular taxonomy for urothelial carcinoma. Clin. Cancer Res. 18, 3377-3386 (2012).
104. Lindgren, D. et al. Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome. Cancer Res. 70, 3463-3472 (2010).
105. Choi, W. et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 25, 152-165 (2014).
106. Damrauer, J. S. et al. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc. Natl Acad. Sci. USA 111, 3110-3115 (2014).
107. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507, 315-322 (2014).
108. McConkey, D. J. et al. Therapeutic opportunities in the intrinsic subtypes of muscle-invasive bladder cancer. Hematol. Oncol. Clin. North Am. 29, 377-394 (2015).
109. Lerner, S. P. et al. Comprehensive characterization of 412 muscle invasive urothelial carcinomas: final analysis of The Cancer Genome Atlas (TCGA) project [abstract]. J. Clin. Oncol. 34 (Suppl. 2S), 405 (2016).
110. McConkey, D. J. et al. A prognostic gene expression signature in the molecular classification of chemotherapy-naïve urothelial cancer is predictive of clinical outcomes from neoadjuvant chemotherapy: a phase 2 trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with bevacizumab in urothelial cancer. Eur. Urol. 69, 855-862 (2016).
111. Bouwman, P. & Jonkers, J. The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. Nat. Rev. Cancer 12, 587-598 (2012).
112. Byrski, T. et al. Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res. Treat. 147, 401-405 (2014).
113. van Allen, E. M. et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov. 4, 1140-1153 (2014).
114. Plimack, E. R. et al. Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer. Eur. Urol. 68, 959-967 (2015).
115. Lee, J. K. et al. A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc. Natl Acad. Sci. USA 104, 13086-13091 (2007).
116. Old, L. J., Clarke, D. A. & Benacerraf, B. Effect of Bacillus Calmette-Guérin infection on transplanted tumours in the mouse. Nature 184 (Suppl. 5), 291-292 (1959).
117. Herr, H. W. & Morales, A. History of Bacillus Calmette-Guérin and bladder cancer: an immunotherapy success story. J. Urol. 179, 53-56 (2008).
118. Rosenberg, J. E. et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387, 1909-1920 (2016).
119. Plimack, E. et al. Pembrolizumab (MK-3475) for advanced urothelial cancer: updated results and biomarker analysis from KEYNOTE-012 [abstract]. J. Clin. Oncol. 33, 4502 (2015).
120. Apolo, A. B. et al. Safety, clinical activity, and PD-L1 expression of avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic urothelial carcinoma from the JAVELIN Solid Tumor phase Ib trial [abstract]. J. Clin. Oncol. 34 (Suppl. 2S), 367 (2016).
121. Massard, C. et al. Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J. Clin. Oncol. 34, 3119-3125 (2016).
122. Sharma, P. et al. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Lancet Oncol. 17, 1590-1598 (2016).
123. Galsky, M. D. et al. Efficacy and safety of nivolumab monotherapy in patients with metastatic urothelial cancer (mUC) who have received prior treatment: results from the phase II CheckMate 275 study [abstract]. J. Clin. Oncol. 34, 4501 (2016).
124. Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252-264 (2012).
125. Balar, A. V. et al. Atezolizumab (atezo) as first-line (1L) therapy in cisplatin-ineligible locally advanced/ metastatic urothelial carcinoma (mUC): primary analysis of IMvigor210 cohort 1 [abstract]. J. Clin. Oncol. 34, LBA4500 (2016).
126. Balar, A. et al. Pembrolizumab (pembro) as first-line therapy for advanced/unresectable or metastatic urothelial cancer: preliminary results from the phase 2 KEYNOTE-052 study [abstract LBA32]. Ann. Oncol. 27 (Suppl. 6), http:\\dx.doi.org/10.1093/annonc/ mdw435.25 (2016).
127. De Santis, M. et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/ carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC Study 30986. J. Clin. Oncol. 30, 191-199 (2012).
128. Food and Drug Administration. Guidance for industry: pathologic complete response in neoadjuvant treatment of high-risk early-stage breast cancer: use as an endpoint to support accelerated approval, 2012. FDA http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/ Guidances/UCM305501.pdf (2014).
129. Zitvogel, L., Apetoh, L., Ghiringhelli, F. & Kroemer, G. Immunological aspects of cancer chemotherapy. Nat. Rev. Immunol. 8, 59-73 (2008).
130. Suzuki, E., Kapoor, V., Jassar, A. S., Kaiser, L. R. & Albelda, S. M. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin. Cancer Res. 11, 6713-6721 (2005).
131. Sawant, A. et al. Enhancement of antitumor immunity in lung cancer by targeting myeloid-derived suppressor cell pathways. Cancer Res. 73, 6609-6620 (2013).
132. Ko, H.-J. et al. A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model. Cancer Res. 67, 7477-7486 (2007).
133. Shevchenko, I. et al. Low-dose gemcitabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer. Int. J. Cancer 133, 98-107 (2013).
134. Ramakrishnan, R. et al. Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. J. Clin. Invest. 120, 1111-1124 (2010).
135. Chen, Z., Xu, X. S., Yang, J. & Wang, G. Defining the function of XPC protein in psoralen and cisplatin-mediated DNA repair and mutagenesis. Carcinogenesis 24, 1111-1121 (2003).
136. Chen, M.-J. et al. Cisplatin depletes TREX2 and causes Robertsonian translocations as seen in TREX2 knockout cells. Cancer Res. 67, 9077-9083 (2007).
137. Galon, J. et al. Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells. FASEB J. 16, 61-71 (2002).
138. Rozkova, D., Horvath, R., Bartunkova, J. & Spisek, R. Glucocorticoids severely impair differentiation and antigen presenting function of dendritic cells despite upregulation of Toll-like receptors. Clin. Immunol. 120, 260-271 (2006).
139. Liu, S. V., Powderly, J. D. & Camidge, D. R. Safety and efficacy of MPDL3280A (anti-PDL1) in combination with platinum-based doublet chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) [abstract]. J. Clin. Oncol. 33, 8030 (2015).
140. Langer, C. J. et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 17, 1497-1508 (2016).
141. Liakou, C. I. et al. CTLA-4 blockade increases IFNβ-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc. Natl Acad. Sci. USA 105, 14987-14992 (2008).
142. Balar, A. V. & Milowsky, M. I. Neoadjuvant therapy in muscle-invasive bladder cancer: a model for rational accelerated drug development. Urol. Clin. North Am. 42, 217-224 (2015).
143. Rosenberg, J. Atezolizumab in patients (pts) with locally-advanced or metastatic urothelial carcinoma (mUC): results from a pivotal multicenter phase II study (IMvigor 210) [abstract 21LBA]. Eur. J. Cancer 51, (Suppl. 3), S720 (2015).
144. Weiss, C. & Rödel, C. Urological cancer: chemoradiation superior in muscle-invasive bladder cancer. Nat. Rev. Clin. Oncol. 9, 374-375 (2012).
145. Mak, R. H. et al. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of radiation therapy oncology group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J. Clin. Oncol. 32, 3801-3809 (2014).
146. James, N. D. et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N. Engl. J. Med. 366, 1477-1488 (2012).
147. Iyer, G. et al. Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. J. Clin. Oncol. 31, 3133-3140 (2013).
148. Iyer, G. et al. Genome sequencing identifies a basis for everolimus sensitivity. Science 338, 221-221 (2012).
149. Martinez-Pineiro, J. A. et al. Original articles: bladder cancer: neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: a prospective randomized phase III study. J. Urol. 153, 964-973 (1995).
150. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02450331 (2016).
151. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02632409 (2016).
152. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02690558 (2016).
153. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02365766 (2016).
154. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02845323 (2016).
155. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02812420 (2016).